PharmaTelevision - Part 1: Is the Emerging Asian Market an opportunity for biotech or pharma?

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Part 1: Is the Emerging Asian Market an opportunity for biotech or pharma?

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this panel discussion Fintan Walton looks at the emerging Asian markets and asks his guests what opportunities they see for different sectors of the industry in this arena. Sandy Macrae, Senior Vice President for GSK's Asia Pacific Japan and Emerging Markets R&D, Ken Macleod, Partner at Paul Capital Healthcare and Bill Guo, Chairman of Venturepharm give their views on this topic following their diverse experiences of the rising Asian biopharma industry.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

GSK's strategy for emerging markets.

Fintan Walton:

Hello and welcome to PharmaVentures business review here at BIO in Atlanta. On this show I have Sandy Macrae, Senior Vice President, Asia Pacific Japan and Emerging Markets Research and Development. I have Ken Macleod, who is a partner at Paul Capital Partners in London.

Ken Macleod:

Thank you Fintan.

Fintan Walton:

And I have Bill Guo, who is the CEO of a company called Venturepharm based in Beijing in China. Welcome to the show. So today we were gonna be talking a little bit about the Emerging markets and is it good for pharma or biotech companies. So I want to turn to you Sandy first of all, GSK you head up a specific group within GSK that focuses on the Emerging Markets in particular the Asian markets you can tell the audience even more specifically about what that goal is but what's clear is that GSK has adopted a new strategy for its position within Emerging Markets, can you just describe that first of all?

Sandy Macrae:

Thank you. GSK thinks the Emerging Markets are clearly very important if you think that China would be the third biggest country in the Emerging Markets by 2012 in the second by 2015 and so we realized that we need to embrace this and find up a portfolio of strategies to be able to bring medicines to these markets. So for that reason we are focusing on vaccines on our branded generics portfolio and on our IP protected medicines. And to help with that we've set up an R&D group which I am looking up to lead which will both look for business development opportunities to bring other peoples medicines into these markets and also a clinical development resource so uniquely we are able to do both business development and clinical development for Asia Pacific and in Emerging Markets.

Fintan Walton:

So basically the basis of that is that you recognize the Emerging Markets as different obviously to the more developed markets and therefore GSK is adapting its growth strategy for those areas specifically?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Bill Guo

Chairman and founder of Venturepharm Group

Dr Sandy Macrae is Senior Vice President for GSK's Asia Pacific Japan and Emerging Markets R&D, a team that seeks and develops medicines for those markets. He trained in medicine and pharmacology at Glasgow University and then specialized in endocrinology at the Royal Postgraduate Medical School, Hammersmith Hospital, London. He has a PhD in genomics from King's College Cambridge and completed his post doctoral research work at Duke University, USA. Sandy first joined SmithKline Beecham(now GlaxoSmithKline) in Neurosciences in 1997. Since then he has held a number of positions including Vice President for Scientific Licensing in Worldwide Business Development, Vice President in Clinical Development for Musculoskeletal, Inflammation, Gastroenterology and Inflammation, and Vice President for Infectious Diseases which included leading their Diseases of the Developing World clinical group. Ken Macleod, Ph.D. joined Paul Capital Partners in 2004 and is responsible for sourcing, evaluating and negotiating European and Asian investment opportunities for Paul Capital Healthcare. Based in London, Dr. Macleod previously held senior management positions over a 15-year career at Serono, Abbott Laboratories, and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation, and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK. Bill Guo is the Chairman and founder of Venturepharm Group, a leading full service provider to world life science industry. Venturepharm Group now has two public companies, Venturepharm Lab, the first China CRO listed in Hong Kong and CBI, the first Chinese CRO's acquisition of a US CRO in NASDAQ. Having obtained the medical degree in China, Bill went to Canada to pursue his MSc and PhD studies in pharmacokinetics and physical \pharmaceuticals at the University of Toronto, and obtained MBA from Herriot Watt University and Executive Education from Judge Business School, University of CambridgeUK. Fortune magazine recognized him as one of the most promising entrepreneurs in China. A list of his awards includes 2005 National Hero by the State Council of China; One of the Ten Best Management Elites in China (2004); one of the ten most influential individuals in economic field of China (2005); Sole winner of Youth Chinese Entrepreneur Award by Asia Business Week (2003); 2005 Entrepreneurs and Innovation by British Chamber of Commerce.

GlaxoSmithKline

GlaxoSmithKline Plc is a United Kingdom based pharmaceutical, biological, and healthcare company. It is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. GSK was formed in 2001 by the merger of GlaxoWellcome (formed from the mergers of Burroughs Wellcome & Company and Glaxo Laboratories), and SmithKline Beecham (from Beecham, and SmithKline Beckman). Paul Capital PartnersPaul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of healthcare companies, institutions and inventors. Today, the firm manages one of the largest dedicated healthcare funds globally with a total of $1.4 billion in assets under management. The Fund focuses on commercial stage healthcare products and investment opportunities in North America, Europe, and Asia. To date Paul Capital Healthcare has closed more than 30 investments in the pharmaceutical, biotechnology, medical device, and diagnostics areas. Public and private companies, research institutions and universities, and individual inventors have all benefited from the flexibility of Paul Capital Healthcare's investment approach. This capital has enabled them to transfer product risk, finance clinical and commercial development projects, acquire new products, fund university programs and capital needs, avoid conflicts of interest, unlock shareholder value, and monetize product royalties. Venturepharm GroupVenturepharm Asia is a global life science leader with a strategic focus on venture capital, merchant banking, CRO, CMO, CSO, compound partnering, and royalty sharing. The group develops an innovative full service plus model to position itself strongly in the life science industry. Currently Venturepharm Asia has more than two thousand employees. Venturepharm is the largest global provider of pharmaceutical development service in China. Venturepharm provides full service of drug discovery and development that take new drugs from "Idea to patients". These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial, product registration, marketing & sales to pharmaceutical distributors and patients in China and overseas. Listed as a Hong Kong public company (8225), Venturepharm (China) has experienced dramatic success since its inception in 1999. Powered with 7 of Smart technology platforms, it has over 400 non-patent infringed products approved, or pending. In addition, 6 of NCEs (new chemical entities) are at preclinical stage. These products encompass over 13 major therapeutic areas. In 2004, Venturepharm was valued by FORTUNE magazine as one of the five most promising companies in China. Since 2000, Venturepharm has achieved revenue CAGR of 133% and EPS CAGR of 383% annually.